Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2025 | Ask the Expert: Petros Grivas answers your bladder cancer questions at ESMO 2025

Petros Grivas • 31 Oct 2025
ESMO 2025
Bladder Cancer Genitourinary Cancer Avelumab Durvalumab Nivolumab Pembrolizumab Tremelimumab
JAVELIN Bladder 100 KEYNOTE-045 KEYNOTE-052 KEYNOTE-361 KEYNOTE-905 NIAGARA TROPiCS-04

Petros Grivas, MD, PhD, University of Washington School of Medicine, Seattle, WA, joins us for an “Ask the Expert” session at ESMO 2025, answering global questions from bladder cancer professionals, including the integration of perioperative immunotherapy in muscle-invasive disease, treatment sequencing with antibody–drug conjugates, the role of molecular profiling, and management of toxicities with enfortumab vedotin plus pembrolizumab. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Petros Grivas

Neoadjuvant pembrolizumab + MVAC in nonurothelial muscle-invasive bladder cancer: Phase II trial
2:23
Neoadjuvant pembrolizumab + MVAC in nonurothelial muscle-invasive bladder cancer: Phase II trial
Petros Grivas • 3 Sep 2025
Phase III clinical trials exploring targeted combination therapies for patients with UC
1:08
Phase III clinical trials exploring targeted combination therapies for patients with UC
Petros Grivas • 20 Oct 2023
Phase Ib trial of bintrafusp alfa for advanced urothelial cancer
1:39
Phase Ib trial of bintrafusp alfa for advanced urothelial cancer
Petros Grivas • 20 Oct 2023
How junior physicians can develop a successful career in medical oncology
2:21
How junior physicians can develop a successful career in medical oncology
Petros Grivas • 20 Oct 2023

Related Videos

Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
3:04
Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
Andrew Armstrong • 3 Jun 2026
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
2:24
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
Andrew Armstrong • 3 Jun 2026
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals